Brief: Tarsus Reports Third Quarter 2022 Financial Results
Nov 9 (Reuters) - Tarsus Pharmaceuticals Inc TARS.O :
* TARSUS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND
RECENT
BUSINESS ACHIEVEMENTS
* NEW DRUG APPLICATION FOR TP-03 ACCEPTED; PDUFA TARGET
ACTION
DATE AUGUST 25, 2023
* CASH RUNWAY ANTICIPATED INTO AT LEAST 2026 FOR PLANNED
COMMERCIAL LAUNCH OF TP-03 AND CONTINUED PIPELINE DEVELOPMENT
* QTRLY LOSS PER SHARE $0.84
* Q3 EARNINGS PER SHARE VIEW $-0.97 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX6PYgwC
Further company coverage: TARS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)